Roivant Sciences (ROIV) Receives a Buy from Piper Sandler
TipRanks (Fri, 24-Jul 8:17 AM ET)
Globe Newswire (Thu, 23-Jul 4:05 PM ET)
Globe Newswire (Thu, 23-Jul 4:05 PM ET)
Market Chameleon (Wed, 20-May 3:56 AM ET)
Globe Newswire (Wed, 20-May 7:00 AM ET)
Globe Newswire (Mon, 11-May 4:05 PM ET)
Globe Newswire (Mon, 11-May 4:05 PM ET)
Market Chameleon (Fri, 6-Feb 6:10 AM ET)
Market Chameleon (Wed, 17-Sep 4:05 AM ET)
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Roivant Sciences Ltd. - Common Shares trades on the NASDAQ stock market under the symbol ROIV.
As of July 24, 2026, ROIV stock price declined to $35.01 with 3,544,243 million shares trading.
ROIV has a beta of 0.79, meaning it tends to be less sensitive to market movements. ROIV has a correlation of 0.09 to the broad based SPY ETF.
ROIV has a market cap of $25.18 billion. This is considered a Large Cap stock.
Last quarter Roivant Sciences Ltd. - Common Shares reported $3 million in Revenue and -$.27 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.09.
In the last 3 years, ROIV traded as high as $37.00 and as low as $8.25.
The top ETF exchange traded funds that ROIV belongs to (by Net Assets): VTI, IJH, VB, VBK, VXF.
ROIV has outperformed the market in the last year with a return of +207.4%, while the SPY ETF gained +17.7%. In the last 3 month period, ROIV beat the market returning +24.4%, while SPY returned +4.6%. However, in the most recent 2 weeks ROIV has underperformed the stock market by returning -4.9%, while SPY returned -1.7%.
ROIV support price is $34.40 and resistance is $35.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ROIV shares will trade within this expected range on the day.
